ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Diagnostic, pharmacological, and ablation approaches for idiopathic ventricular fibrillation: the 2024 European Heart Rhythm Association survey.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of the European Heart Rhythm Association (EHRA) physician-based survey was to assess current clinical practice regarding the diagnostic assessment and therapeutic management of idiopathic ventricular fibrillation (IVF) across European Society of Cardiology (ESC) countries and to evaluate adherence to the 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. METHODS AND
resultsAn online 24-item was developed and disseminated by the Scientific Initatives Committee of EHRA. A total of 206 physicians from 41 countries completed the questionnaire. Respondents declaring a full diagnostic assessment of IVF, including at least coronary angiogram/cardiac computed tomography scan, electrocardiogram monitoring, exercise stress test, pharmacological challenges, and cardiac magnetic resonance, were 71 (35%). Cardiac magnetic resonance, sodium channel blocker test, and genetic testing were reported by 51, 34, and 43%, respectively. The most preferred first-line therapeutic strategy in case of recurrent implantable cardioverter-defibrillator (ICD) shocks was drug therapy (88%). In case of first-line strategy failure, the preferred reported strategy was ablation (53%).
conclusionThis survey highlights a significant heterogeneity of the diagnostic approach to IVF with underuse of crucial examinations. In line with guideline recommendation, drug therapy is more often considered as first-line therapy and ablation as second-line therapy for recurrent ICD shocks. However, quinidine is considered as drug of choice by <25% of respondents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.